We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Invited Commentary |

Implantable Cardioverter/Defibrillators in the Primary Prevention of Sudden Death: We Know What to Do but Are We Doing It?  Comment on: “Optimal Medical Therapy Use Among Patients Receiving Implantable Cardioverter-Defibrillators”

Paul J. Hauptman, MD
Arch Intern Med. 2012;172(1):67-68. doi:10.1001/archinternmed.2011.468.
Text Size: A A A
Published online


The mandate to weigh risks and benefits for use of cardiac rhythm devices (specifically implantable cardioverter/defibrillators [ICDs]) for the primary prevention of sudden cardiac death is substantial, given the cost of the devices and their potential impact on patient outcomes including health-related quality of life. Recent studies have demonstrated that comorbidities such as renal failure,1,2 underuse of β-blockers,3 and inappropriate timing of implants4 are all in play. In their analysis, Miller and colleagues5 use data from the National Cardiovascular Data Registry (NCDR) to assess whether patients undergoing device implantation with reduced ejection fraction are receiving optimal medical therapy (OMT) for congestive heart failure.5 This is a descriptive analysis for the period January 2007 to June 2009 that relies on NCDR reports by the participating institution of medication use at discharge. Given the limitations of the NCDR (for example, the lack of linkage to patient and pharmacy records), the investigators do not have information about antecedent and subsequent medication adherence or medication dosing. Furthermore, the authors acknowledge that, as for many NCDR data elements, on-site auditing was not performed on the medication variable.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.